Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04139200
Other study ID # S62902
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 22, 2020
Est. completion date December 11, 2023

Study information

Verified date January 2024
Source KU Leuven
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of mortality and morbidity around the world. Studies revealed that patients with COPD are less active than age-matched healthy controls and activity level decreases with disease severity. Higher levels of physical activity is related to important health-related outcomes, such as lower mortality rate and hospital admissions. Additionally, increasing physical activity is related with substantial health benefits. Patients with COPD have a higher risk of developing insulin resistance, hypertension, dyslipidemia, osteopenia, leading to chronic diseases such as coronary heart disease, type 2 diabetes and osteoporosis, which have been related to physical inactivity in the healthy population. Moreover, physical inactivity has been related to the occurrence of comorbidities in patients with COPD. Therefore, improving physical activity levels is a recommended treatment in the disease management in all patients with COPD and is implemented in the recent GOLD guidelines for all patients with COPD, regardless of the disease severity. The research group investigated the effect of a 3-month semi-automatic tele-coaching intervention on physical activity levels in patients with COPD. The tele coaching intervention led to a significant improvement on physical activity in the intervention group. Although this trial showed positive results on physical activity, further research is needed, mainly to investigate the long-term (12 months) effectiveness of such interventions and the added value of a smartphone application on top of a simple step counter providing feedback. Additionally, since physical activity is related to the development of comorbidities, the investigators aim to explore the influence of improving physical activity levels on the occurrence of cardiovascular, metabolic and musculoskeletal comorbidities. Finally, this study will explore baseline characteristics (such as social support, self-efficacy, dynamic hyperinflation, etc.) that can predict success in this intervention.


Description:

The aims of the present study are: 1. primary objective: To investigate the changes in physical activity after a 12-month tele coaching intervention (including individualized goal setting, feedback, motivational contacts with coach and a step counter providing direct feedback), compared to a sham group receiving a light coaching intervention (feedback from step counter and static goal setting, without additional motivation or contact with the coach). 2. secondary objectives: A. Investigate the effect of a 12-month tele coaching intervention on exercise capacity, muscle force, quality of life, physical activity from a patient's perspective, dyspnea-related fear and comorbidities. B. Confirming previous findings on short-term effects (or lack of effect) of the tele coaching intervention on physical activity, exercise capacity and quality of life, assessed at 6 months. C. Identifying possible baseline characteristics that are determinants of the change in physical activity after the 12-month tele coaching intervention. D. Investigating the association between the pattern in vital signs (including physical activity, resting heart rate, heart rate variability, heart rate recovery, oxygen saturation, respiratory rate) as measured by a wearable and the onset of an exacerbation. E. To explore the relation between dynamic hyperinflation as measured during the six-minutes walk test, physical activity measured at baseline and change in physical activity as result of the intervention. F. Investigate the effect of an acute exacerbation on functional performance (only in Ghent). G. Investigate the association between a change in physical activity and autonomic function (only in Ghent). H. Validity and reliability of wearable devices to measure autonomic function, respiratory rate and oxygen saturation (only in Ghent). Therefore, the study will include stable patients with COPD (post bronchodilator FEV1/FVC < 0.70) with no moderate or severe exacerbations in the past month, across all disease severities. For patients in UZ Leuven and UZ Ghent, the study will consists of 4 clinical visits: - Visit 1 screening visit - Visit 2: randomization visit, scheduled 1-2 weeks after visit 1 - Visit 3: short term follow-up visit, scheduled 6 months after visit 2 - Visit 4: long-term follow-up visit, scheduled 12 months after visit 2 Only for patients in UZ Ghent: to investigate the effect of an acute COPD exacerbation on functional performance, an additional visit will take place when the patient experiences an exacerbation after the first 6 months of the study. This visit will take place as soon as possible and maximally 14 days after onset of the symptoms. If the patient does not experience an exacerbation during the first year of the study, the patient will be followed-up until occurrence of the first exacerbation or up to 30 months (whichever occurs first) with intermediate visits at 18 months and 24 months. All patients included in the study will be randomized in either the intervention group or sham group: - A multicomponent tele coaching intervention that consists of 1) education about the importance of physical activity and a one-to-one interview with the coach discussing the motivation and barriers to be active, 2) a step counter providing direct feedback, 3) application installed on a smartphone providing an adaptive goal and daily and weekly feedback and 4) contact with the coach if the patient is not compliant with the intervention, not increasing physical activity or when the patient reports a change in medication. The patient is asked to have a daily interaction with the smartphone application. - A sham intervention that consist of 1) education about the importance of physical activity and a personal (fixed) goal expressed in terms of steps. The patient is asked to try to reach this goal, 2) a step counter providing direct feedback, 3) application installed on a smartphone only displaying a graph with the activity of the present week and the personal (fixed) goal, 4) contact with the coach if the patient reports a change in medication. The patient is asked to have at least a weekly interaction with the application. - Only in UZ Ghent: in case of extended follow-up after 12 months, patients will receive the multicompenent tele coaching intervention after 12 months of inclusion in the study.


Recruitment information / eligibility

Status Completed
Enrollment 150
Est. completion date December 11, 2023
Est. primary completion date December 11, 2023
Accepts healthy volunteers No
Gender All
Age group 40 Years and older
Eligibility Inclusion Criteria: 1. Patients diagnosed with COPD (GOLD criteria post bronchodilator FEV1/FVC < 0.70) 2. Patients under medical follow-up of a respiratory physician or general practitioner with no moderate (ambulatory treated) and/or severe (requiring a hospital admission) exacerbation in the past month 3. Older than 40 years old 4. Smoking history with more than 10 pack years Exclusion Criteria: 1. The presence of orthopedic or other problems not allowing an increase in physical activity levels 2. Unable to learn to work with a new electronic device (e.g. smartphone), as judged by the investigator 3. Underwent lung transplantation or active on the lung transplantation list 4. Involved in or planned to start with a structured multidisciplinary rehabilitation program

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Type 1 physical activity tele coaching intervention
A) Education about the importance of PA. During a one-to-one interview with the coach motivation, self-efficacy, barriers, favorite activities and strategies to become more active are discussed. B) Step counter providing direct feedback. C) A smartphone with a project-tailored application. The application provides automated coaching by displaying an activity goal (number of steps) and feedback on a daily basis. The feedback comes with a graphical presentation. Patients' targets are automatically revised weekly. The aim is to progressively increase the PA during the 12 weeks period and maintain afterwards. D) Telephone contacts triggered in the case of non-compliance with wearing the step counter, failure to transmit data, failure to progress or change in medication. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed.
Type 2 physical activity tele coaching intervention
A) Education about the importance of PA. During a one-to-one interview with the investigator, patients will receive a personal goal (expressed in steps/day), based on their individual exercise capacity. B) A step counter providing direct feedback. C) A smartphone with a project-tailored application. The application receives the step data of the patient and asks on a weekly basis about the patient's change in medication. The application does provide a graph showing the steps the patient took and presents a general activity plan including their personal goal (which stays the same throughout the entire intervention period). D) Telephone contacts triggered in the case of change in medication. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed.

Locations

Country Name City State
Belgium UZ Gent Ghent
Belgium UZ Leuven Leuven

Sponsors (2)

Lead Sponsor Collaborator
KU Leuven University Ghent

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Daily number of steps at 12 months Change in daily mean step count 12 months post randomization in the intervention group as compared to the control group. Physical activity will be objectively measured for 1 week using a tri-axial accelerometer validated for use in patients with COPD. At least 4 valid weekdays (> 8 hours of wearing time during waking hours) is necessary to label the physical activity measurement as valid. 12 months
Secondary Daily number of steps at 6 months Change in daily mean step count 6 months post randomization in the intervention group as compared to the control group. Physical activity will be objectively measured for 1 week using a tri-axial accelerometer validated for use in patients with COPD. At least 4 valid weekdays (> 8 hours of wearing time during waking hours) is necessary to label the physical activity measurement as valid. 6 months
Secondary Minutes per day spent in at least moderate intense activities Change in minutes per day spent in at least moderate intense activities 6 and 12 months post randomization in the intervention group as compared to the control group. Physical activity will be objectively measured for 1 week using a tri-axial accelerometer validated for use in patients with COPD. At least 4 valid weekdays (> 8 hours of wearing time during waking hours) is necessary to label the physical activity measurement as valid. 6 months and 12 months
Secondary Mean walking time per day Change in mean daily walking time 6 and 12 months post randomization in the intervention group as compared to the control group. Physical activity will be objectively measured for 1 week using a tri-axial accelerometer validated for use in patients with COPD. At least 4 valid weekdays (> 8 hours of wearing time during waking hours) is necessary to label the physical activity measurement as valid. 6 months and 12 months
Secondary Mean sedentary time per day Change in mean sedentary time 6 and 12 months post randomization in the intervention group as compared to the control group. Physical activity will be objectively measured for 1 week using a tri-axial accelerometer validated for use in patients with COPD. At least 4 valid weekdays (> 8 hours of wearing time during waking hours) is necessary to label the physical activity measurement as valid. 6 months and 12 months
Secondary Exercise capacity Change in six-minutes walk distance 6 and 12 months post randomization in the intervention group as compared to the control group. The six-minutes walk test will be performed with standardized encouragement to assess patients' functional exercise capacity. The best of two measurements will be used. 6 months and 12 months
Secondary Quadriceps force Change in quadriceps force 6 and 12 months post randomization in the intervention group as compared to the control group. The quadriceps isometric strength will be evaluated by a maximal voluntary contraction using the Biodex, a computerized dynamometer. Patients will be seated with a 90° hip and 60° knee flexion. The best of 4 measurements will be taken into analysis as the maximal force capacity of the lower limb. 6 months and 12 months
Secondary Health status Change in health status 6 and 12 months post randomization in the intervention group as compared to the control group. Health status will be measured by COPD assessment test (CAT), a validated, 8-item questionnaire to assess the impact of the disease on a patient's health status. Scores range from 0 to 40, with a higher score indicating a worse health status. The minimal clinical important difference (MCID) is a change of 3 points. 6 and 12 months
Secondary Health related quality of life: CRDQ-SAS Change in health related quality of life 6 and 12 months post randomization in the intervention group as compared to the control group. Health status will be measured by Chronic Respiratory Disease Questionnaire; self-administrated standardized version (CRDQ-SAS), measuring both physical and emotional aspects of chronic respiratory disease. The questionnaire contains 20 items, spread over 4 domains (dyspnea, fatigue, emotional function and mastery). The minimal clinical important difference is reflected by a change in score of 0.5 on a 7-point scale. 6 months and 12 months
Secondary Physical activity from a patients' perspective Change in physical activity from a patients' perspective 6 and 12 months post randomization in the intervention group as compared to the control group. This will be measured by PROactive tool (clinical visit version), a validated 12-item questionnaire assessing physical activity from a patient's perspective reflecting the past 7 days. The questionnaire investigates the amount of and difficulty with physical activity as perceived by the patient. The 2 domain scores (i.e. amount and difficulty) as well as the total score will be retrieved as outcomes. Subscores and total score are from 0 to 100, with higher score meaning less problems with daily life activities as reported by the patient. 6 months and 12 months
Secondary Dyspnea-related fear Change in dyspnea-related fear 6 and 12 months post randomization in the intervention group as compared to the control group. This will be measured by breathlessness beliefs questionnaire (BBQ), an 17-item questionnaire investigating the dyspnea-related anxiety in patients with respiratory diseases. Score ranges from 17 to 85. Higher values indicate worse dyspnea-related fear. 6 months and 12 months
Secondary Symptoms of anxiety and depression Change in symptoms of anxiety and depression 12 months post randomization in the intervention group as compared to the control group. Symptoms of anxiety and depression will be measured by the Hospital Anxiety and Depression Scale (HADs). The HADs is a generic screening measure of symptoms of anxiety and depression. The HADS is a 14 item measure comprising 7 anxiety items and 7 depression items from which separate anxiety and depression sub-scale scores are calculated, ranging from 0 to 21 for both sub domains. A score of 8 or higher indicates a high possibility of anxiety / depression 12 months
Secondary Functional performance To investigate the effect of an acute COPD exacerbation on functional performance, functional performance will be measured by the Short physical performance battery (SPPB), timed up and go test (TUG) and 1-minute sit-to-stand (1' STS) as soon as possible (and maximally 14 days) after onset of an exacerbation. Only in Ghent - as soon as possible and max 14 days after the occurrence of an COPD exacerbation
Secondary Autonomic function Exploring the association between change in physical activity and autonomic function. To evaluate the autonommic fuction, the patient will wear a Polar chest band with corresponding watch for 7 consecutive days (day and night). Based on this measurement we will retrieve measures on: respiratory rate; resting heart rate (heart rate during the night); heart rate variability. Data will be processed using Kubios software.
The Polar chest band with corresponding watch will also be worn while performing the 6-minute walking test as measures of HRV during exercise and heart rate recovery (HRR). Data will be processed using Kubios software.
Only in Ghent - 6 months and 12 months; additionally at 18 months and 24 months in case of extended design
Secondary Autonomic symptoms Exploring the association between change in physical activity and autonomic fuction, To evaluate autonomic symptoms, autonomic symptoms will be measured by the COMPASS 31 questionnaire. This questionnaire contains six domains: orthostatic intolerance, vasomotor, secrotomotor, gastrointestinal, urinary and pupillomotor function. Total score ranges from 0 to 100, with higher score indicating more autonomic dysfunction. Only in Ghent - 6 months and 12 months; additionally at 18 months and 24 months in case of extended design
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06000696 - Healthy at Home Pilot
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04043728 - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study N/A
Completed NCT04105075 - COPD in Obese Patients
Recruiting NCT05825261 - Exploring Novel Biomarkers for Emphysema Detection
Active, not recruiting NCT04075331 - Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial Phase 2/Phase 3
Terminated NCT03640260 - Respiratory Regulation With Biofeedback in COPD N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
Withdrawn NCT04210050 - Sleep Ventilation for Patients With Advanced Hypercapnic COPD N/A
Terminated NCT03284203 - Feasibility of At-Home Handheld Spirometry N/A
Recruiting NCT06110403 - Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness Phase 1/Phase 2
Active, not recruiting NCT06040424 - Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Recruiting NCT04868357 - Hypnosis for the Management of Anxiety and Breathlessness During a Pulmonary Rehabilitation Program N/A
Completed NCT01892566 - Using Mobile Health to Respond Early to Acute Exacerbations of COPD in HIV N/A
Completed NCT04119856 - Outgoing Lung Team - a Cross-sectorial Intervention in Patients With COPD N/A
Completed NCT04485741 - Strados System at Center of Excellence
Completed NCT03626519 - Effects of Menthol on Dyspnoea in COPD Patients N/A
Recruiting NCT04860375 - Multidisciplinary Management of Severe COPD N/A